JPRN-jRCT1052230085
招募中
2 期
A Phase II Study to Evaluate the Efficacy and Safety of Deep-Inspiration Breath-Hold Daily Adaptive Radiotherapy in Centrally Located Lung Tumors - PUDDING-STUDY
Takashi Mizowaki0 个研究点目标入组 25 人2023年8月12日
概览
- 阶段
- 2 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Primary lung tumor
- 发起方
- Takashi Mizowaki
- 入组人数
- 25
- 状态
- 招募中
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\) Patients aged 20 years or older
- •2\) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •3\) Central lung tumors 5 cm or less (central lung tumor is defined according to IASLC recommendations: located 2 cm or less from mediastinum, including bronchus, esophagus, heart, brachial plexus, vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve)
- •4\) Ability to hold breath for at least 20 seconds
- •5\) Indicated for stereotactic body radiotherapy or hypofractionated radiotherapy by a radiation oncologist.
- •6\) Written informed consent to participate in the study is obtained
排除标准
- •1\) Patients with interstitial pneumonia
- •2\) who are not expected to live 3 months or longer, according to the physician
- •3\) who are unable to consent to participate in the study
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.Crohn's DiseaseMedDRA version: 19.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2012-004098-26-DEAstraZeneca AB120
进行中（未招募）
1 期
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.Crohn's DiseaseMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2012-004098-26-CZAstraZeneca AB120
进行中（未招募）
1 期
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.Crohn's DiseaseMedDRA version: 18.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2012-004098-26-FRAstraZeneca AB121
进行中（未招募）
1 期
Evaluation of efficacy and safety of MEDI2070 in patients with active,moderate-to-severe Crohn's disease.EUCTR2012-004098-26-ITASTRAZENECA120
进行中（未招募）
1 期
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn´s disease.EUCTR2012-004098-26-ESAstraZeneca AB120